Canaccord backs bullish outlook for Vascular Solutions

Canaccord is out reiterating a Buy recommendation on shares of Vascular Solutions (VASC) as analyst Jason Mills sees "double-digit revenue and EPS growth" going forward, thanks to "solid core business and continued strong execution."

In a colorful note, Mills calls the preliminary injunction against BSX's Guidezilla extension catheter an "early Christmas present" and says "potential new reprocessing service could add more 'steak & sizzle' to the VASC story within 12 months."

Price target hiked to $25 from $22.50.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs